[1]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,(07):39-43.[doi:10.3969/j.issn.1006-1959.2019.07.014]
 WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Medical Information,2019,(07):39-43.[doi:10.3969/j.issn.1006-1959.2019.07.014]
点击复制

肺癌患者血浆检测肿瘤标志物的分析方法及展望()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
39-43
栏目:
综述
出版日期:
2019-04-01

文章信息/Info

Title:
Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer
文章编号:
1006-1959(2019)07-0039-05
作者:
魏优蕾郭晓彤
(哈尔滨医科大学附属第二医院胸外二科,黑龙江 哈尔滨 150001)
Author(s):
WEI You-leiGUO Xiao-Tong
(Department of Thoracic Surgery,Subject Two,the Second Affiliated Hospital of Harbin Medical University,Harbin 150001,Heilongjiang,China)
关键词:
肺癌肿瘤标志物液体检测
Keywords:
Lung cancerTumor markersLiquid detection
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.07.014
文献标志码:
A
摘要:
非小细胞肺癌(NSCLC)患者进行靶向治疗前需要鉴定多种生物标志物,包括EGFR、ALK、ROS-1和PD-L1,通常经手术、穿刺等途径获取样本。液体检测是目前新兴的肿瘤标记物检测方法,它可以从血浆中提取出循环系统中的肿瘤DNA(ctDNA),具有低风险、取样简单、术后不适感少等优点。常用的液体活检方法有定量聚合酶链反应(PCR)、数字PCR技术、新一代测序技术(NGS)。本文简要地阐述了上述分析方法的研究进展及未来应用方向。
Abstract:
Non-small cell lung cancer (NSCLC) patients need to identify a variety of biomarkers, including EGFR, ALK, ROS-1 and PD-L1, before they are targeted. Usually, the samples are obtained by surgery, puncture and other means. Liquid detection is an emerging method for detecting tumor markers. It can extract tumor DNA (ctDNA) from the circulatory system from plasma, and has the advantages of low risk, simple sampling, and less postoperative discomfort. Commonly used liquid biopsy methods are quantitative polymerase chain reaction (PCR), digital PCR technology, and next-generation sequencing technology (NGS). This paper briefly describes the research progress and future application directions of the above analytical methods.

参考文献/References:


[1]Hida T,Nokihara H,Kondo M,et al.Alectinib versus crizotinib in patients with ALK-positive nonsmall-cell lung cancer(J-ALEX):an open-label,randomised phase 3 trial[J].Lancet,2017, 390(10089):29-39.
[2]Shaw AT,Ou SH,Bang YJ,et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,371(21):1963-1971.
[3]Wang S,Yu B,Ng CC,et al.The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer[J].Transl Lung Cancer Res,2015,4(2):119-125.
[4]Malapelle U,Bellevicine C,De Luca C,et al.EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients[J].Cancer Cytopathol,2013,121(10):552-560.
[5]Sacher AG,Komatsubara KM,Oxnard GR.Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review[J].J Thorac Oncol,2017,12(9):1344-1356.
[6]Karachaliou N,Mayo-de las Casas C,Queralt C,et al.Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial[J].JAMA Oncol,2015,1(2):149-157.
[7]Malapelle U,Pisapia P,Rocco D,et al.Next generation sequencing techniques in liquid biopsy:focus on non-small cell lung cancer patients[J].Transl Lung Cancer Res,2016,5(5):505-510.
[8]Malapelle U, Mayo de-Las-Casas C,Rocco D,et al.Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients[J].Br J Cancer,2017,116(6):802-810.
[9]Pantel K,Speicher MR.The biology of circulating tumor cells[J].Oncogene,2016,35(10):1216-1224.
[10]Rolfo C,Giallombardo M,Reclusa P,et al.Exosomes in lung cancer liquid biopsies:two sides of the same coin?[J].Lung Cancer,2017(104):134-135.
[11]Crowley E,Di Nicolantonio F,Loupakis F,et al.Liquid biopsy: monitoring cancergenetics in the blood[J].Nat Rev Clin Oncol,2013,10(8):472-484.
[12]Mead R,Duku M,Bhandari P,et al.Circulating tumour markers can define patients with normal colons, benign polyps, and cancers[J].Br J Cancer,2011,105(2):239-245.
[13]Normanno N,Denis MG,Thress KS,et al.Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-smallcell lung cancer[J].Oncotarget,2017,8(7):12501-12516.
[14]Toro PV,Erlanger B,Beaver JA,et al.Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA[J].Clin Biochem,2015,48(15):993-998.
[15]Schmidt B,Reinicke D,Reindl I,et al.Liquid biopsy-Performance of the PAXgene Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients[J]. Clin Chim Acta,2017(469):94-98.
[16]Page K,Guttery DS,Zahra N,et al.Influence of plasma processing on recovery and analysis of circulating nucleic acids[J].PLoS One,2013,8(10):e77963.
[17]Tie J,Kinde I,Wang Y,et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer[J].Ann Oncol,2015,26(8):1715-1722.
[18]Mauger F,Dulary C,Daviaud C,et al.Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma[J].Anal Bioanal Chem,2015,407(22):6873-6878.
[19]Mayo-de-Las-Casas C,Garzón Ibánez M,Jordana-Ariza N,et al.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer[J].Expert Rev Mol Diagn,2018,18(1):35-45.
[20]Douillard JY,Ostoros G,Cobo M,et al.Gefitinib treatment in EGFR mutated caucasian NSCLC:circulating-free tumor DNA as a surrogate for determination of EGFR status[J].J Thorac Oncol,2014,9(9):1345-1353.
[21]Kimura H,Kasahara K,Kawaishi M,et al.Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer[J].Clin Cancer Res,2006,12(13):3915-3921.
[22]Kim HR,Lee SY,Hyun DS,et al.Detection of EGFR mutationsin circulating free DNA by PNA-mediated PCR clamping[J].J Exp Clin Cancer Res,2013,32(1):50.
[23]Kimura H,Suminoe M,Kasahara K,et al.Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib(IRESSA)[J].Br J Cancer,2007,97(6):778-784.
[24]Goto K,Ichinose Y,Ohe Y,et al.Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS,a phase Ⅲ study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J].J Thorac Oncol,2012,7(1):115-121.
[25]Douillard JY,Ostoros G,Cobo M,et al.First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV,open-label,single-arm study[J].Br J Cancer,2014,110(1):55-62.
[26]Pasquale R,Fenizia F,Esposito Abate R,et al.Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients[J].Pharmacogenomics,2015,16(10):1135-1148.
[27]Thress KS,Brant R,Carr TH,et al.EGFR mutation detection in ctDNA from NSCLC patient plasma:A cross-platform comparison of leading technologies to support the clinical development of AZD9291[J].Lung Cancer,2015,90(3):509-515.
[28]Malapelle U,de Luca C,Vigliar E,et al.EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR:a validation study[J].J Clin Pathol,2016,69(5):454-457.
[29]Vendrell JA,Mau-Them FT,Béganton B,et al.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management[J].Int J Mol Sci,2017,18(2):18.
[30]Yung TK,Chan KC,Mok TS,et al.Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients[J].Clin Cancer Res,2009,15(6):2076-2084.
[31]Sacher AG,Paweletz C,Dahlberg SE,et al.Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer[J].JAMA Oncol,2016,2(8):1014-1022.
[32]Oxnard GR,Thress KS,Alden RS,et al.Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer[J].J Clin Oncol,2016,34(28):3375-3382.
[33]Mok TS,Wu YL,Ahn MJ,et al.AURA3 Investigators.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J].N Engl J Med,2017,376(7):629-640.
[34]Bentley DR,Balasubramanian S,Swerdlow HP,et al.Accurate whole human genome sequencing using reversible terminator chemistry[J].Nature,2008,456(7218):53-59.
[35]Rothberg JM,Hinz W,Rearick TM,et al.An integrated semiconductor device enabling non-optical genome sequencing[J].Nature,2011,475(7356):348-352.
[36]Li J,Batcha AM,Grüning B,et al.An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology[J].Cancer Inform,2016,14(Suppl 5):87-107.
[37]Clinical and Laboratory Standards Institute.Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine;Approved Guideline (CLSI document MM09-A2)[M].2nd ed.Wayne(PA):Clinical and Laboratory Standards Institute,2014.
[38]Couraud S,Vaca-Paniagua F,Villar S,et al.BioCAST/IFCT-1002 investigators.Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002[J].Clin Cancer Res,2014,20(17):4613-4624.
[39]Reckamp KL,Melnikova VO,Karlovich C,et al.A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma[J].J Thorac Oncol,2016,11(10):1690-1700.
[40]Paweletz CP,Sacher AG,Raymond CK,et al.Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients[J].Clin Cancer Res,2016,22(4):915-922.
[41]Newman AM,Bratman SV,To J,et al.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J].Nat Med,2014,20(5):548-554.
[42]Normanno N,Maiello MR,Chicchinelli N,et al.Targeting the EGFR T790M mutation in nonsmall-cell lung cancer[J].Expert Opin Ther Targets,2017,21(2):159-165.
[43]Piotrowska Z,Niederst MJ,Karlovich CA,et al.Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor[J].Cancer Discov,2015,5(7):713-722.
[44]Remon J,Menis J,Hasan B,et al.The APPLE Trial:Feasibility and Activity of AZD9291(Osimertinib)Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients.EORTC 1613[J].Clin Lung Cancer,2017,18(5):583-588.

相似文献/References:

[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
 YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Medical Information,2018,(07):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹晓美,王莉娜.肺癌患者疾病不确定感的影响因素与干预措施研究现状[J].医学信息,2018,(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
 DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Medical Information,2018,(07):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]邢益辉,刘 曼,厉玛倩倩,等.快速康复对肺癌手术患者并发症发生及生活质量的影响研究[J].医学信息,2018,(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
 XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Medical Information,2018,(07):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[4]朱晓晓,张 顺,蔡 挺.镍暴露相关的肺癌发生分子机制研究[J].医学信息,2018,(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
 ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Medical Information,2018,(07):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[5]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(07):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[6]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
 LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Medical Information,2018,(07):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[7]付云杰.肺癌患者血浆D-二聚体、NSE及CYFRA21-1联合检测的临床价值[J].医学信息,2018,(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
 FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Medical Information,2018,(07):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[8]覃柳麻,何慧敏.2014~2016年广西肿瘤医院肺癌患者流行病学及病理分布特征分析[J].医学信息,2019,(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
 QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Medical Information,2019,(07):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[9]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
 YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Medical Information,2019,(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]

更新日期/Last Update: 2019-04-01